FFAR1 and type 2 diabetes mellitus: Among various FFAR1 agonists described till date [8], [11]–[15], fasiglifam is the most advanced clinical candidate for the treatment of T2DM, showing a potent antidiabetic effect comparable with that of sulfonylureas in early-stage clinical trials, with a lower propensity to cause hypoglycemia in healthy volunteers and diabetic patients [16]–[19].